全文获取类型
收费全文 | 55篇 |
免费 | 11篇 |
专业分类
儿科学 | 27篇 |
基础医学 | 2篇 |
临床医学 | 2篇 |
内科学 | 6篇 |
特种医学 | 1篇 |
肿瘤学 | 28篇 |
出版年
2024年 | 1篇 |
2021年 | 1篇 |
2020年 | 3篇 |
2019年 | 2篇 |
2018年 | 6篇 |
2017年 | 4篇 |
2016年 | 3篇 |
2015年 | 2篇 |
2014年 | 1篇 |
2013年 | 4篇 |
2012年 | 2篇 |
2011年 | 2篇 |
2010年 | 1篇 |
2008年 | 2篇 |
2007年 | 3篇 |
2005年 | 4篇 |
2004年 | 1篇 |
2003年 | 4篇 |
2002年 | 1篇 |
2001年 | 4篇 |
2000年 | 1篇 |
1999年 | 3篇 |
1998年 | 1篇 |
1997年 | 2篇 |
1994年 | 1篇 |
1993年 | 1篇 |
1992年 | 2篇 |
1989年 | 1篇 |
1988年 | 1篇 |
1987年 | 1篇 |
1986年 | 1篇 |
排序方式: 共有66条查询结果,搜索用时 0 毫秒
41.
Detection of disseminated tumor cells in neuroblastoma: 3 log improvement in sensitivity by automatic immunofluorescence plus FISH (AIPF) analysis compared with classical bone marrow cytology
下载免费PDF全文
![点击此处可从《The American journal of pathology》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Méhes G Luegmayr A Kornmüller R Ambros IM Ladenstein R Gadner H Ambros PF 《The American journal of pathology》2003,163(2):393-399
The sensitive detection of bone marrow involvement is crucial for tumor staging at diagnosis and for monitoring of the therapeutic response in the patient's follow-up. In neuroblastoma, only conventional cytomorphological techniques are presently accepted for the detection of bone marrow involvement, yet since the therapeutic consequences of the bone marrow findings may be far-reaching, the need for highly reliable detection methods has become evident. For this purpose, we developed an automatic immunofluorescence plus FISH (AIPF) device which allows the exact quantification of disseminated tumor cells and the genetic verification in critical cases. In this study, the power of the immunofluorescence technique is compared with conventional cytomorphology. 198 samples from 23 neuroblastoma patients (stages 4 and 4s) at diagnosis and during follow-up were investigated. At diagnosis, 45.6% of the samples (26 of 57) which were positive by AIPF investigation were negative by cytomorphology. During follow-up, 74.2% (49 of 66) of AIPF-positive samples showed no cytological signs of tumor cell involvement. False negative morphological results were found in up to 10% of tumor cell content. A tumor cell infiltrate below 0.1% was virtually not detectable by conventional cytomorphology. Using the sensitive immunofluorescence technique, the analysis of only two instead of four puncture sites did not lead to false negative results. Thus, the immunofluorescence technique offers an excellent tool for reliable detection and quantification of disseminated tumor cells at diagnosis and during the course of the disease. 相似文献
42.
Alberto Garaventa Olivier Hartmann Jean-Louis Bernard Jean-Marie Zucker Nuria Pardo Vittoria Castel Sandro Dallorso Zora Adelbost Ruth Ladenstein Franck Chauvin Thierry Phillip 《Pediatric blood & cancer》1994,22(1):11-14
This survey includes 25 children with Wilms' tumor undergoing high-dose chemotherapy associated with autologous bone marrow transplantation (ABMT) in the period June 1984-December 1991 and enrolled in the European Bone Marrow Transplantation Registry for Solid Tumors. At diagnosis, 12 children presented stage IV disease, 5 stage III, 3 stage II, and 5 stage I. Before ABMT, 21 children had 1 to 4 relapses (median 1); 13 achieved a second or subsequent complete remission (CR), four stage IV children failed to respond to first line treatment and achieved either CR (3 patients), or partial remission (PR) after second line therapy. At high-dose chemotherapy, 17 children were in CR and 8 had measurable disease. Seven different high-dose regimens were administered, even if 20 children received melphalan mostly associated with vincristine and 8 involved field radiotherapy. Three children died early of pneumonitis; 2 developed an acute transient renal failure, 1 a chronic renal failure. Out of the 8 children with target disease at graft, 2 died of toxicity, 5 achieved CR, 1 obtained PR, and only 1 is presently alive in CCR at 39 months after ABMT. Of the 17 children grafted in CR, 8 are alive event-free at 14-90 months (median 34) from ABMT; 7 relapsed at 3-23 months (median 7 months); 1 died of toxicity and 1 was lost to follow-up in CR at 12 months. A salvage attempt with high-dose chemotherapy in children with resistant or poor prognosis recurrent Wilms' tumor seems to be justified. An international cooperative protocol taking into account the increased risk of lung and renal toxicity is necessary. © 1994 Wiley-Liss, Inc. 相似文献
43.
T. Philip R. Ladenstein J. M. Zucker R. Pinkerton E. Bouffet D. Louis W. Siegert J. L. Bernard D. Frappaz C. Coze et al. 《British journal of cancer》1993,67(1):119-127
In the LMCE1 study using a single course of megatherapy most of the relapses occurred during the first 2 years after autologous bone marrow transplantation. A second pilot study (LMCE2) was therefore set up using a double harvest/double graft approach with two different megatherapy regimens. Objectives were to test the role of increased dose intensity on response status, relapse pattern and overall survival. Thirty-three patients (20 boys, 13 girls) with a median age of 53 months at first megatherapy (range, 17-202 months) entered this study. They were cases either with refractory disease in partial response after second line treatment for stage 4 neuroblastoma (n = 25) or after relapse from stage 4 (n = 5) or stage 3 disease (n = 3). All patients received Etoposid and/or Cisplatinum (or Carboplatin) containing treatments before megatherapy. The first megatherapy regimen was a combination of Tenoposid, Carmustine and Cisplatinum (or Carboplatin), the second applied Vincristin, Melphalan and Total Body Irradiation. The first harvest was scheduled 4 weeks after the last chemotherapy, the second 60 to 90 days after megatherapy. All marrows were purged in vitro by an immunomagnetic technique. Median follow up time since first megatherapy is 56 months. Response rates for evaluable patients were 65% (complete response rate: 16%) for megatherapy 1 and 60% (complete response rate: 25%) for megatherapy 2. Considering that only patients with delayed response or relapse were eligible for this pilot study the overall survival was encouraging with 36% at 2 years and still 32% at 5 years. The costs for these survival rates were high in terms of morbidity (four early and four late toxic deaths; toxic death rate: 24%). Double harvesting may have the disadvantage of delayed engraftments related in part to a disturbance of marrow microenvironment by megatherapy 1. This double megatherapy approach achieved a prolonged relapse free interval (median 11 months, range 2-31 months) in patients reaching megatherapy 2 and justifies further evaluation of concepts with consecutive dose-escalation. 相似文献
44.
Monika Sparber-Sauer Maximilian Dietzschold Anton Schönstein Amadeus Heinz Christian Vokuhl Kristian W. Pajtler Semi Harrabi Yi-Lan Lin Thekla von Kalle Rudolf Hagen Ruth Ladenstein Bernarda Kazanowska Gustaf Ljungman Thomas Klingebiel Martin Ebinger Ewa Koscielniak Marc Münter Beate Timmermann the CWS Study Group 《Pediatric blood & cancer》2024,71(1):e30742
45.
46.
Tumour volume reduction after neoadjuvant chemotherapy impacts outcome in localised embryonal rhabdomyosarcoma
下载免费PDF全文
![点击此处可从《Pediatric blood & cancer》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Tobias M. Dantonello Monika Stark Beate Timmermann Jrg Fuchs Barbara Selle Christin Linderkamp Rupert Handgretinger Rudolf Hagen Simone Feuchtgruber Stefanie Kube Daniel Kosztyla Bernarda Kazanowska Ruth Ladenstein Felix Niggli Gustaf Ljungman Stefan S. Bielack Thomas Klingebiel Ewa Koscielniak 《Pediatric blood & cancer》2015,62(1):16-23
47.
The genetic tumor background is an important determinant for heterogeneous MYCN‐amplified neuroblastoma
下载免费PDF全文
![点击此处可从《International journal of cancer. Journal international du cancer》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Dominik Bogen Clemens Brunner Diana Walder Andrea Ziegler Reza Abbasi Ruth L. Ladenstein Rosa Noguera Tommy Martinsson Gabriele Amann Freimut H. Schilling Marek Ussowicz Martin Benesch Peter F. Ambros Inge M. Ambros 《International journal of cancer. Journal international du cancer》2016,139(1):153-163
Amplification of MYCN is the signature genetic aberration of 20–25% of neuroblastoma and a stratifying marker associated with aggressive tumor behavior. The detection of heterogeneous MYCN amplification (hetMNA) poses a diagnostic dilemma due to the uncertainty of its relevance to tumor behavior. Here, we aimed to shed light on the genomic background which permits hetMNA in neuroblastoma and tied the occurrence to other stratifying markers and disease outcome. We performed SNP analysis using Affymetrix Cytoscan HD arrays on 63 samples including constitutional DNA, tumor, bone marrow and relapse samples of 26 patients with confirmed hetMNA by MYCN‐FISH. Tumors of patients ≤18m were mostly aneuploid with numeric chromosomal aberrations (NCAs), presented a prominent MNA subclone and carried none or a few segmental chromosomal aberrations (SCAs). In older patients, tumors were mostly di‐ or tetraploid, contained a lower number of MNA cells and displayed a multitude of SCAs including concomitant 11q deletions. These patients often suffered disease progression, tumor dissemination and relapse. Restricted to aneuploid tumors, we detected chromosomes with uniparental di‐ or trisomy (UPD/UPT) in almost every sample. UPD11 was exclusive to tumors of younger patients whereas older patients featured UPD14. In this study, the MNA subclone appears to be constraint by the tumor environment and thus less relevant for tumor behavior in aggressive tumors with a high genomic instability and many segmental aberrations. A more benign tumor background and lower tumor stage may favor an outgrowth of the MNA clone but tumors generally responded better to treatment. 相似文献
48.
Gilles Vassal MD PhD Edel Fitzgerald MA Martin Schrappe MD PhD Frédéric Arnold MSc Jerzy Kowalczyk MD PhD David Walker BMedSci BM BS Lars Hjorth MD PhD Riccardo Riccardi MD Anita Kienesberger MA Kathy‐Pritchard Jones PhD FRCP Maria Grazia Valsecchi PhD Dragana Janic MD PhD Henrik Hasle MD PhD Pamela Kearns PhD MBChB FRCPCH Giulia Petrarulo MA Francesco Florindi MA Samira Essiaf MSc Ruth Ladenstein MD PhD MBA cPM 《Pediatric blood & cancer》2014,61(9):1551-1557
In Europe, 6,000 young people die of cancer yearly, the commonest disease causing death beyond the age of 1 year. In addition, 300,000–500,000 European citizens are survivors of a childhood cancer and up to 30% of them have severe long‐term sequelae of their treatment. Increasing both cure and quality of cure are the two goals of the European paediatric haematology/oncology community. SIOPE coordinates and facilitates research, care and training which are implemented by the 18 European study groups and 23 national paediatric haematology/oncology societies. SIOPE is the European branch of the International Society of Paediatric Oncology and one of the six founding members of the European Cancer Organisation. SIOPE is preparing its strategic agenda to assure long‐term sustainability of clinical and translational research in paediatric malignancies over the next 15 years. SIOPE tackles the issues of equal access to standard care and research across Europe and improvement of long term follow up. SIOPE defined a comprehensive syllabus for training European specialists. A strong partnership with parent, patient and survivor organisations is being developed to successfully achieve the goals of this patient‐centred agenda. SIOPE is advocating in the field of EU policies, such as the Clinical Trials Regulation and the Paediatric Medicine Regulation, to warrant that the voice of young people is heard and their needs adequately addressed. SIOPE and the European community are entirely committed to the global agenda against childhood cancers to overcome the challenges to increasing both cure and quality of cure of young people with cancer. Pediatr Blood Cancer 2014;61:1551–1557. © 2014 Wiley‐Liss, Inc., A Wiley Company. Pediatric Blood & Cancer published by Wiley Periodicals, Inc. 相似文献
49.
Richard Sullivan Jerzy R Kowalczyk Bharat Agarwal Ruth Ladenstein Edel Fitzgerald Ronald Barr Eva Steliarova-Foucher Ian Magrath Scott C Howard Mariana Kruger Maria Grazia Valsecchi Andrea Biondi Paul Grundy Malcolm A Smith Peter Adamson Gilles Vassal Kathy Pritchard-Jones 《The lancet oncology》2013,14(3):e125-e135
50.
Poorly differentiated, neuron-specific enolase positive round cell tumor with two translocations t(11;22) and t(21;22) 总被引:1,自引:0,他引:1
The authors describe a highly malignant, disseminated round cell tumor originating in the ninth rib of a 14-year-old boy. Extensive studies by means of light and electron microscopic examination, histocytochemistry and immunocytochemistry and cytogenetic analysis revealed an undifferentiated, neuron-specific enolase positive round cell tumor with a unique karyotype: 45,XY,-21,t(11;22)(q23;q11), der(22)t(21;22)(q11.2;p11). Thus, despite the absence of definite morphologic features, such as Homer-Wright rosettes, neurosecretory granules and cytoplasmatic processes, these findings suggest a neuroectodermal origin of this bone tumor. 相似文献